Among disease-modifying treatments (DMT) in MS therapy, NAT is associated with an increased risk of progressive multifocal leukoencephalopathy (PML) especially in John Cunningham virus (JCV) positive and long-term treated patients (8). Here, BRD2 is linked to myeloid sarcoma.